Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...

Tariff wars and macro woes have impacted investor sentiment, weighing on stocks across various sectors. However, healthcare ...

With age comes wisdom. But you know what else can come with age? Weight gain. Losing weight can also be harder as you grow ...

Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.

The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...